Clene Nanomedicine, Inc.

Home
Clene Nanomedicine, Inc.

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. www.clene.com

Thank you for your interest in Clene Nanomedicine! This is an exciting time for us. We have been receiving many requests for more information. We hope you understand we cannot respond to individual requests. We instead invite you to visit our website, read our press releases, and check back for updates!

12/03/2025

Today Clene Nanomedicine, Inc. announced that a cross-regimen analysis of data from Regimens A and C of the Healey ALS Platform Trial revealed new evidence of a survival benefit in participants treated with Clene’s novel nanocatalytic investigational drug, . The analysis was enabled using data from concurrently enrolled participants in Regimen A of the Healey ALS Platform Trial. These data support and strengthen existing survival benefit and NfL biomarker data from multiple clinical trials and EAP analyses.

Read more: https://invest.clene.com/news-releases/news-release-details/clene-demonstrates-strengthened-als-survival-benefit-cnm-au8r

19/12/2024

Clene Nanomedicine, Inc. (NASDAQ: $CLNN) announces the signing of a new debt facility with an aggregate total of $10M, targeted to close by Dec. 20, 2024. The proceeds will be used to analyze data on for the treatment of . These data include new analyses from three Expanded Access Programs requested by the FDA to support an NDA via an accelerated approval pathway.

Read more: https://invest.clene.com/news-releases/news-release-details/clene-improves-cash-position-and-runway-securing-new-debt

10/12/2024

FDA provides Clene Nanomedicine (NASDAQ:$CLNN) with feedback on a potential accelerated approval pathway for CNM-Au8®

For today’s Press Release from Clene Nanomedicine (NASDAQ: $CLNN) of Dec. 10, 2024 see: https://www.globenewswire.com/news-release/2024/12/10/2994554/0/en/FDA-Provides-Roadmap-for-Accelerated-Approval-Pathway-Through-Submission-of-Additional-CNM-Au8-Biomarker-Data-in-ALS.html

05/12/2024

Clene Nanomedicine, Inc. (NASDAQ: $CLNN) is thrilled to be presenting four posters at the 35th International Symposium on ALS/MND in Montreal, Canada, Dec. 6-8. Come talk to us during Poster Sessions A and B and learn more about the long-term safety and efficacy of in treating !

03/12/2024

Our own Marjan Sepassi, PharmD, will be presenting on “CNM-Au8 Long-term Evidence and EAP Program Update” tomorrow, December 4, 2024 at 4 PM PT / 7 PM ET at the next hosted by EverythingALS.

Don’t miss the latest news from Clene Nanomedicine, Inc. (NASDAQ: $CLNN)!

Register here: everythingals.org/events

02/12/2024

Clene Nanomedicine, Inc. (NASDAQ: $CLNN)’s CEO and President Rob Etherington and CSO Mark Mortenson recently presented how the novel nanomedicine was innovated using techniques from electrochemistry and solid state physics. They then revealed how CNM-Au8 has performed in Phase 2 clinical trials, demonstrating survival benefits and safety in . They were interviewed by Buck Joffey on the Sapio Podcast. Tune in! Links below.

Apple Podcast: https://podcasts.apple.com/us/podcast/111-nanoparticles-in-neurodegenerative-disease-treatment/id1688677939?i=1000678181541

Spotify: https://open.spotify.com/episode/4mCfu7qKkkhtt0RreHpWv3?si=XyIC08usTMCtCtncayVXCw

YouTube: https://youtu.be/5tg6R_Cv9_U

29/10/2024

? About 90% of people diagnosed with have no known family history of or genetic cause for this debilitating disease.

Learn more from The ALS Association to increase your :
https://bit.ly/3e3BsCk

24/10/2024

Neuronal energy deficits occur in neurodegenerative diseases like , resulting in neuronal dysfunction and death.

Our nanotherapeutic supports energy production in neurons to help restore healthy neuron function.

Learn more: https://bit.ly/3VrtSs0

22/10/2024

: Earlier this month, Merit Cudkowicz, MD, MSc, Robert P. Bowser, Ph.D., and Clene Nanomedicine, Inc.’s Head of Medical Benjamin Greenberg, MD, MHS, FAAN, presented an update on the long-term data for in a Northeast ALS Consortium (NEALS) Meeting webinar moderated by Jinsy Andrews, MD, MSc, FAAN.

In the webinar, the panel discussed emerging long-term evident of biomarker data, survival and ALS clinical worsening improvements in response to CNM-Au8 treatment.

Watch it now: https://bit.ly/3YhTMhY

17/10/2024

: Our very own Karen S. Ho, PhD, VP of Translational Medicine, shared her experience transitioning from academic to biotech research and spelled out Clene Nanomedicine, Inc.’s vision for treating neurodegenerative diseases with nanoparticle-based therapeutics.

Check it out:
https://bit.ly/3yeU6VM

09/10/2024

Happy National Nanotechnology Day from Clene Nanomedicine, Inc.! Today, we celebrate the many improvements that can make in our lives across a broad range of applications.

Learn more about how we leverage -therapeutics in our pipeline: https://bit.ly/3J9LcbH

03/10/2024

Clene Nanomedicine, Inc. is grateful to have received a fantastic metal print of the artwork depicting ’s neuroprotective action made for our cover issue of the top-tier nanoscience journal Small (Wiley) from Ella Maru Studio.

Thanks for the wonderful gift, Ella Marushchenko!

Address

Telephone

+18016769695

Website

http://www.clene.com/

Alerts

Be the first to know and let us send you an email when Clene Nanomedicine, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Clene Nanomedicine, Inc.:

Shortcuts

Address
Telephone
Alerts
Contact The Practice
Claim ownership or report listing
Want your practice to be the top-listed Clinic?

Country:

City:

Applying Nanocatalysis to Neurodegenerative Diseases

Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease, has innovated a novel nanotechnology platform to create a new class of drugs—bioenergetic nanocatalysts. Clene’s lead drug candidate, CNM-Au8, is a concentrated nanocrystalline gold (Au) suspension that drives critical cellular bioenergetic reactions in the CNS. CNM-Au8 increases cellular energy to accelerate neuro repair and improve neuroprotection. Currently, CNM-Au8 is being investigated for efficacy and safety in a Phase 3 registration trial for ALS and in Phase 2 trials for multiple sclerosis and Parkinson’s disease. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based in Salt Lake City, Utah with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com.